You are about to leave the website of Otsuka Novel Products GmbH and view the content of an external website. Otsuka Novel Products GmbH cannot be held responsible for the content of external websites.
Treatment of multidrug-resistant TB (MDR-TB) takes a minimum of 9, and sometimes even 20 months.
Such prolonged treatment requires extensive capacity from health providers to diagnose the disease and choose the correct treatment regimen, support patients in their daily intake of medicines, and manage any adverse effects that may appear.
Otsuka has been involved in a series of public health projects to strengthen treatment capacity in some of the developing countries most affected by the disease.
For example, a project in Indonesia in partnership with a local university evaluated existing practices in TB and MDR-TB care in various hospitals and identified gaps and interventions needed to effectively manage the disease. A smartphone application was also developed to support patients throughout treatment.
Information current as of 26-06-2017